Product Description
an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19250823/)
Mechanisms of Action: EP2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Tibial Fractures|Fractures, Closed
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2008-004183-38 | P2 |
Completed |
Unknown |
2010-05-13 |
|
| A3241010 | P2 |
Completed |
Tibial Fractures |
2010-05-01 |
|
| JapicCTI-080569 | P2 |
Completed |
Tibial Fractures|Fractures, Closed |
None |